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Copyright # 200ABSTRACT: The ultimate goal of any cancer therapy is to target the elimination of neoplastic cells. Although newer
therapeutic strategies are in constant development, therapeutic assessment has been hampered by the inability to assess,
rapidly and quantitatively, efficacy in vivo. Diffusion imaging and, more recently, sodium MRI have demonstrated their
distinct abilities to detect therapy-induced alterations in tumor cellularity, which has been demonstrated to be indicative of
therapeutic efficacy. More importantly, both imaging modalities detect tumor response much earlier than traditional
methodologies that rely on macroscopic volumetric changes. In this study, the correlation between tumor sodium and
diffusion was further tested to demonstrate the sensitivity of sodium imaging to gauge tumor response to therapy by using a
9L rat gliosarcoma treated with varying doses of BCNU [1,3-bis(2-chloroethyl)-1-nitrosourea]. This orthotopic model has
been demonstrated to display variability in response to BCNU therapy where initial insult has been shown to lead to drug-
resistance. In brief, a single 26.6mg/kg BCNU dose yielded dramatic responses in both diffusion and sodiumMRI. However,
a second equivalent BCNU dose yielded a much smaller change in diffusion and sodium, suggesting a drop in tumor
sensitivity to BCNU. The MRI responses of animals treated with 13.3mg/kg BCNU were much lower and similar responses
were observed after the initial and secondary applications of BCNU. Furthermore, these results were further validated using
volumetric measurements of the tumor and also ex vivo determination of tumor sensitivity to BCNU. Overall, these
experiments demonstrate the sensitivity and applicability of sodium and diffusion MRI as tools for dynamic assessment of
tumor response to therapy. Copyright # 2006 John Wiley & Sons, Ltd.KEYWORDS: tumor; diffusion; sodium; magnetic resonance imaging; 1,3-bis(2-chloroethyl)-1-nitrosourea; BCNU;
chemotherapy resistanceINTRODUCTION
Within solid tumors lies a heterogeneous mass of cells
that may exhibit variable growth rates and, more
importantly, drug sensitivities that may play a role in
the unpredictability of tumor response to therapy. Since
tumors are heterogeneous by nature, a tremendous need
exists for a standardized approach to benchmark tumor
response efficiently and rapidly. To achieve such a feat
would provide tremendous gains for preclinical devel-
opment of experimental therapeutics where novelto: V. D. Schepkin, National High Magnetic Field
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6 John Wiley & Sons, Ltd.strategies could be dynamically evaluated throughout
treatment. More importantly, there are clear clinical
implications where rapid assessment of therapeutic
efficacy could lead to opportunities to optimize thera-
peutic protocols in reaction to changes in tumor response
to therapy. In response to this need, diffusion MRI has
been demonstrated as a powerful tool for quantitative
assessment of tumor response to therapeutic insult by
observing the microscopic changes in water diffusion that
occur as a result of cellular destruction (1).
A multitude of studies have validated the applicability
of diffusion MRI, in both preclinical and clinical models,
for providing early assessment of therapeutic efficacy as
well as a predictor of therapeutic outcome (2–10). The
benefit of diffusion MRI arises from the exploitation of
the biophysical property of water diffusion, which is
highly sensitive to microscopic changes in cellular
structure. Moreover, these microscopic changes precede
eventual macroscopic changes in tumor volume, which
occur at much later stages after therapeutic insult.
Similarly, other biomarkers could potentially be utilized
to provide an indication of cellularity such as tissueNMR Biomed. 2006; 19: 1035–1042
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lar sodium concentrations are highly regulated during
normal physiology; therefore, any disruption in cellular
integrity can lead to abnormal imbalances that are
detectable using sodium MRI. Since both diffusion and
sodium MRI rely on biophysical properties driven by
changes in cellular structure, sodiumMRI should provide
similar reliability and efficiency for assessing tumor
response to therapy. Recently, sodium MRI has garnered
attention where studies have provided a glimpse into the
utility of this approach to observe tumor response to
chemotherapy in a variety of model systems (11–13).
However, sodium imaging, both technically and its
translational application in oncology, has yet to be fully
realized and is currently under investigation (14–26).
In this study, sodium and diffusion MRI, applied
concurrently, were further explored as tools for providing
a quantitative readout of tumor response to therapy. The
well-characterized 9L gliosarcoma tumor model has been
historically demonstrated to exhibit the emergence of
drug resistance in response to initial BCNU [1,3-bis(2-
chloroethyl)-1-nitrosourea] therapy (27–31). Using this
model system, this study was aimed at ascertaining
the correlation between sodium and diffusion imaging
and their sensitivity to measure quantitatively tumor
responses, which can thereby serve as a sensitive
biomarker of therapy-induced cellular changes. By
concurrently employing diffusion MRI, the results
demonstrated that sodium MRI indeed provided early
indication of changes in TNa that paralleled changes in
ADC. Moreover, by employing two dosing regimens with
groups receiving either two doses of 13.3mg/kg or
26.6mg/kg BCNU, both imaging methods were further
demonstrated to be highly sensitive in discerning
differences in tumor response between both treatment
groups, which was later verified by observable differences
in tumor volume. In addition, sodium and diffusion
imaging detected an apparent shift in BCNU sensitivity
due to the emergence of drug resistance, which was
confirmed with ex vivo BCNU sensitivity assays of tumor
samples demonstrating a measurable shift in drug
sensitivity. In conclusion, these findings taken together
further validate the utility of sodium and diffusionMRI as
a quantitative and rapid approach for dynamic assessment
of tumor response.METHODS
Cell culture
Rat 9L gliosarcoma cells (passage 12) from the
Brain Tumor Research Center at the University of
California at San Francisco were maintained and grown
as monolayer cultures in Dulbecco’s modified Eagle’s
medium (DMEM) supplemented with 10% (v/v) heat-
inactivated fetal bovine serum, 100 IU/mL penicillinCopyright # 2006 John Wiley & Sons, Ltd.and 100mg/mL streptomycin at 378C in a normally
humidified atmosphere containing a 95:5 (v/v) air–CO2
mixture. Prior to implantation, cells were grown to 90%
confluence in a 175-cm2 flask, harvested using a 0.25%
trypsin–0.1% EDTA solution and counted using a Coulter
cell counter. Cells were pelleted and re-suspended in
serum-free DMEM at a concentration of 1 105 cells per
10mL and kept on ice until use. Cell culture reagents were
obtained from Invitrogen Life Technologies (Carlsbad,
CA, USA).Tumor implantation
Male Fisher 344 rats (n¼ 15) weighing 75 g (Harlan,
Indianapolis, IN, USA) were anesthetized by intraper-
itoneal (IP) injection using an 87:13 (v/v) ketamine–
xylazine mixture. Under aseptic conditions, 9L
cells, prepared as described previously, were injected
subcutaneously into the right flank. A total volume
of 50mL was injected, containing approximately 5 105
9L cells.Chemotherapy
Approximately 13 days after tumor implantation, 15
tumor-bearing rats were divided into three parts: five for
the control group and two groups of five each for
treatment with two different BCNU doses. The average
tumor size at the time of treatment (13 days after tumor
implantation) in all groups was 380 130mL. The treated
groups received BCNU therapy. A standard 100-mg
BCNU preparation (Bristol-Meyers, Princeton, NJ, USA)
was dissolved in ethanol and further diluted with 100%
saline as recommended by the manufacturer. The freshly
prepared BCNU solution was immediately used for
single-dose IP injections of 13.3mg/kg (1) and 26.6mg/
kg (2) for the first and second treated animal groups,
respectively. In the same fashion, the same doses of
BCNU were given again when both tumor ADC and
sodium reached pretreatment values. The second BCNU
administration was performed in 14 and 21 days after the
first intervention for the 1 and 2 groups, respectively.
All animal experiments were conducted according to the
protocols approved by the University of Michigan
Committee on Use and Care of Animals.
Magnetic resonance imaging
Sodium and proton MRI were performed concurrently
every 2–3 days on all animals until closure of the
experiment when tumors reached an excessive volume.
Proton and sodiumMR scans were performed using a 9.4-
T MR scanner (120-mm clear horizontal bore) (Varian,
Palo Alto, CA, USA) and a double-tuned volume RF coil
with an internal diameter of 34mm and length of 65mmNMR Biomed. 2006; 19: 1035–1042
DOI: 10.1002/nbm
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temperature was maintained during MRI scans by using a
temperature-controlled circulating water heating pad.
Anesthesia was maintained at a 1.25% (v/v) isoflurane–
air mixture throughout image acquisitions.Sodium MRI
The tumor region of the rat was placed at the center of the
RF coil. The axial length of the RF coil homogeneous
region (deviation < 5%) was approximately 20mm,
which was sufficient to encompass the spatial extent of
the tumors and allow quantitative tumor sodium imaging.
Because sodium has short T2 relaxation time components,
a 3D back-projection pulse sequence was used (32). In the
original spin-echo 3D back-projection pulse sequence
(Varian), two hard pulses provided an echo time of
1000ms. The other parameters included readout gradient
1.3G/cm, field of view (FOV) 64 64 64mm, 64
complex points in the readout direction using 32 32
projections, repetition time TR¼ 0.1 s and scan time
approximately 28min. The duration of the 908 pulse was
50ms. In these experiments, the sodium T1 relaxation
time in normal rat muscle was 37 1ms at 9.4 T, thus
yielding an almost unsaturated Naþ signal during 3D
imaging. Reconstructions were performed using the
Varian Back-Projection software and Matlab (v. 7.0.1).
Data were zero-filled to 256 points prior to Fourier
transformation. The final axial output sodium images
were made by summing eight adjacent slices together to
achieve a comparable slice to slice separation with
diffusion proton images.Proton MRI
The protocol for proton multi-slice diffusionMRI utilized
the following parameters: FOV¼ 40 40mm, acqui-
sition matrix 128 128, 15 slices, slice thick-
ness¼ 1.5mm, slice gap¼ 0.5mm, TR¼ 3 s and echo
time (TE)¼ 40ms. The diffusion spin-echo pulse
sequence employed isotropic diffusion weighting by
orthogonalization of x-, y- and z-gradient waveforms (33).
Specifically, the imaging plus diffusion gradient wave-
forms were designed to equalize diagonal elements and
zero-out off-diagonal elements of the b-matrix. In
addition, this sequence included first-order flow com-
pensation and a 32-point navigator echo for motion
correction prior to image reconstruction. Diffusion
weighted images (DWI) at two-b-factor settings were
acquired for calculation of ADC maps: ‘high-b’
(b¼ 1082 s/mm2) and ‘low-b’ (b¼ 117 s/mm2). The total
diffusion scan time was 18min. Proton images and ADC
maps were reconstructed in Matlab and the tumor volume
and average ADC values were determined over a 3D
volume of interest (VOI) for each temporal measurement.Copyright # 2006 John Wiley & Sons, Ltd.Quantification and analysis
Three-dimensional sodium images were co-registered to
the target proton multi-slice ADCmap image set. Use of a
double-tuned coil minimized the demands for the co-
registration procedure. This process placed all images on
to a common geometric frame, allowing the tumor VOI
definition to be performed on available higher quality
images. Tumor sodium concentration was determined as
an average for all voxels over the 3D tumor volume
determined by ADC image at each time point.
For quantification of sodium measurements, sodium
MR signals were acquired using adjusted 908 pulses
and compared with three references samples consisting
of saline solutions with 38, 77 and 154mM NaCl.
The size of these reference samples (diame-
ter length¼ 30 65mm) was chosen to fill the working
space of the RF coil. The differences in RF coil loading
between animals and between reference samples were
determined from duration of the RF pulse required to
achieve a sodium 908 flip angle for each animal. The
found pulse durations were used during Na signal
quantification to correct the difference in coil sensitivity
at the different coil loads. Sodium concentrations were
presented as mM per volume of tissue detected by MRI.
Each animal had sodium MRI and ADC map
measurements performed in axial planes throughout the
tumor. Reproducibility of the imaging experimental
conditions was assessed by stability of Naþ signal intensity
and ADC measurements in the contra-lateral flank regions.
Results of all ADC and sodium concentration measure-
ments are presented as average SEM. Tumor volumes
were normalized to 1 at the time of treatment.Ex vivo BCNU sensitivity assay
Tumors were excised from the animals at the end of MRI
experiments. Three or more animals were used for the ex
vivo assay in each group. In the group treated with a 1
dose of BCNU, tumor cells were extracted at day 14 after
initiation of therapy. In the group treated with a 2 dose
of BCNU, tumor cells were extracted at day 21. Cells
from untreated control tumors were taken from animals
21 days after tumor implantation. In vitro resistance
tests were performed using the sulforhodamine assay
(34). All cell lines were analyzed at the same time to
minimize possible errors. Cells were seeded at a density
of 4000 cells/well in 96-well plates. After 24 h, the cells
were treated with seven dilutions of BCNU ranging from
0.0 to 200mM. Cells were allowed to grow until the
untreated cells reached confluence and then were fixed
and stained with sulforhodamine B (SRB). A microtiter
colorimetric analysis system (FluorStar, BMG Lab
Technologies, Germany) was used to measure the
absorbance at 490 nm, which corresponded to the amount
of viable cells. Each cell line (control, 1 and 2 BCNU)NMR Biomed. 2006; 19: 1035–1042
DOI: 10.1002/nbm
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The final cell count data for different BCNU concen-
trations were fitted by exponential decay functions to
determine the inhibition parameters IC50.RESULTS
Sodium and diffusion imaging
Representative images are shown in Fig. 1, demonstrating
the effect of BCNU therapy on a 9L subcutaneous tumor
as visualized by both sodium and diffusionMRmaps over
time. As shown in Fig. 1(A), the untreated tumor has
lower ADC values than normal muscle and the tumor can
be seen as a low-intensity mass on the diffusion image. In
contrast, the corresponding sodium image of the untreated
tumor displays a distinguishably higher TNa versus
normal muscle tissue. However, at day 8 after BCNU
treatment, large increases in both ADC and TNa [Fig.
1(B) and (E), respectively] were observed. In addition,
tumor response as detected by both sodium and diffusion
MRI was very inhomogeneous, which was especially
apparent during tumor repopulation [Fig. 1(C) and (F)].
Therefore, in order to monitor therapeutic efficacyFigure 1. Proton ADC mapping (A–C)
sodium MR images (D–F) of a 9L rat sub
chemotherapy. The images were taken
time points after a single 2 (26.6mg/kg
pretreated tumor are shown at the lef
images taken at days 8 and 17 after ini
tumor ADC and tumor sodium can be se
17, tumor re-population can be seen as
region within the tumor on the ADC m
low Naþ concentration on the 23Na MR
Copyright # 2006 John Wiley & Sons, Ltd.throughout the time course, only the average values of
TNa and ADC throughout the tumor were used.Tumor diffusion
The dynamic changes in tumor ADC as detected by
diffusion MRI during the treatment course of a 9L rat
subcutaneous tumor using two different doses of BCNU
were quantified and are presented in Fig. 2. ADC values in
untreated control tumors remained relatively constant
[(1.04 0.02) 103mm2/s] throughout the experiment.
However, a modest increase of tumor ADC up to
(1.34 0.02) 103mm2/s was detected 6 days after
treatment with 1 dose of BCNU [Fig. 2(A)]. The
estimated rate of ADC increase during 3 days after the
initial 1 dose of BCNU was (0.06 0.02) 103mm2/
s/day. A second equivalent dose of BCNU was admi-
nistered on day 14 and yielded another ADCmaximum of
(1.31 0.06) 103mm2/s at approximately 5 days
after the second intervention with a corresponding
initial rate of ADC increase at the level of
(0.08 0.02) 103mm2/s/day [Fig. 2(A)]. Neither the
maximum change nor the rate of change between the two
groups were statistically different (p> 0.05).and corresponding co-registered
cutaneous tumor following BCNU
from the same animal at different
) dose of BCNU: the images of the
t (A, D), and are followed by the
tiation of therapy. Heterogeneous
en at day 8 post-treatment. At day
a reduced (low-diffusion) intensity
ap, which also corresponds to the
image.





















































Figure 2. Changes in tumor diffusion throughout BCNU therapy. BCNU-treated
(*) and untreated controls (*). BCNU doses were (A) 1¼13.3mg/kg and (B)
2¼26.6mg/kg.
PROTON DIFFUSION AND SODIUM MRI 1039Using the 2 BCNU dose, a dramatically different
response was observed [Fig. 2(B)]. The first administration
of BCNU produced a very intense increase in tumor ADC
from the non-treated value of (1.04 0.02) 103mm2/s
up to a maximum of (1.87 0.06) 103mm2/s at day 9
post-treatment. Moreover, a higher average rate of increase
in ADC, comparedwith the 1 dose BCNU treatment, was
found: (0.12 0.025) 103mm2/s/day. Upon reaching
the initial ADC value and at the onset of tumor re-growth
on day 21, a second equivalent dose of BCNU (2) was
administered. A considerably reduced rate of tumor ADC
increase of (0.05 0.01) 103mm2/s/day) was observed
compared with the rate detected subsequent to the initial
dose of BCNU and only a fraction of the previous
ADC maximum of (1.20 0.03) 103mm2/s was
achieved. These data reveal a significant change in both
the rate of change andmaximum diffusion change between
the two doses indicating that a reduced sensitivity to
BCNU (i.e. gain of resistance) had occurred following the
initial treatment dose. The second maximum ADC in this




























Figure 3. Changes in tumor sodium throug
and untreated controls (*). BCNU doses
2¼26.6mg/kg.
Copyright # 2006 John Wiley & Sons, Ltd.comparison, the mean ADC values in contra-lateral
normal flank tissue, which were measured at the same
time as the tumor values, remained at the level of
(1.27 0.02) 103mm2/s for both doses of BCNU
therapy.Tumor sodium
The time courses of TNa as detected by sodium MRI
throughout therapy with either 1 or 2 doses of BCNU
are shown in Fig. 3. The initial level of sodium in
untreated tumors was found to be 43.0 0.6mM. For
comparison, the Naþ concentration in contra-lateral
normal flank tissue was 21.1 0.9mM.
When a 1 dose of BCNU was given, TNa within the
tumor increased at an initial rate of 4.1 0.5mM/day and
reached a maximum of 63.2 4mM on day 5 post-
treatment [Fig. 3(A)]. Following a second 1 dose of
BCNU, a similar pattern of TNa change was observed,




























hout BCNU therapy. BCNU-treated (*)
were (A) 1¼13.3mg/kg and (B)
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the initial administration of BCNU. More importantly,
changes in TNa over time due to the therapeutic insult
were highly correlative with changes in ADC within the
same time frame.
Using a 2 dose of BCNU, a similar pattern of TNa
change [Fig. 3(B)] over time was observed as detected
earlier for ADC [Fig. 2(B)]. The first BCNU injection
produced a dramatic increase in TNawith an initial rate of
9.8 1.3mM/day and a maximum of TNa (104 14mM)
was reached at day 8. The average tumor sodium content
returned to the pretreatment level in 21 days, which is
comparable to the time course detected by diffusion MRI.
The second 2 dose of BCNU treatment yielded a greatly
diminished response, as evidenced by a greatly depressed
increase in TNa [Fig. 2(B)]. The maximum tumor TNa
was not clearly distinguishable as a slow tumor TNa
increase usually observed in untreated tumors at the late
stages of tumor growth.Tumor volume
In order to validate our diffusion and sodium MRI
findings and to ascertain the utility of each approach for
assessing therapeutic efficacy, volumetric measurements
over the course of therapy were obtained to observe
discernible changes in tumor growth kinetics. A
comparison of the changes in tumor volumes in the
control group versus changes in tumor volumes in
the treated groups is shown in Fig. 4. Tumor volume in the
untreated group increased quickly by 8-fold in 9 days
with a volumetric doubling time of 3.1 0.5 days.
Treatment of tumors with the first 1 dose of BCNU
resulted in an 8-day tumor growth delay. Following the
second 1 dose of BCNU, a more pronounced decrease in
tumor doubling time (9.3 0.8 days) was found versus
control tumors as determined by fitting of the volumetric















































Figure 4. Volumetric tumor growth measurements over time. BCNU-treated
(*) and untreated controls (*). Tumor volumes were normalized to 1 at the
time of treatment. BCNU doses were (A) 1¼13.3mg/kg and (B)
2¼26.6mg/kg.Copyright # 2006 John Wiley & Sons, Ltd.In the group that received a 2 dose of BCNU,
significant growth inhibition was detectable as the tumor
increased less than 2-fold at 10 days post-onset of therapy
[Fig. 4(B)] which was followed by a decrease in volume
until day 19, at which time tumor re-growth began. At this
time, a second equivalent dose of BCNU was adminis-
tered that further delayed tumor growth until day 30.
Interestingly, as is apparent in Fig. 4(B), the second dose
of 2 BCNU produced a diminished growth delay
compared with the initial dose of BCNU, suggesting that
perhaps the tumor was less sensitive to the second dose.Ex vivo assessment of tumor BCNU
resistance
To provide insight into tumor responsiveness after BCNU
therapy, tumors from each group were excised and tested
for alteration in BCNU sensitivity. For untreated control
tumors, the IC50 was found to be 42 5mM (Table 1).
When tumors were treated with a 1 dose of BCNU,
increased resistance to BCNU was revealed
(IC50¼ 54 4mM, Table 1), which was not statistically
different from the control (p> 0.05). In the case of
animals receiving a 2 dose of BCNU (Table 1), a
significant resistance to BCNU was detected as shown by
a nearly 50% increase in IC50 (IC50¼ 62 1mM,
p< 0.01) compared with untreated controls.DISCUSSION
Current methods for assessing tumor response to therapy
rely mainly on macroscopic changes in volume or
alterations in survival as markers of efficacy, which
require a significant time for these outcomes to be
achieved. A tremendous need exists for rapid and
noninvasive quantitative imaging of therapeutic response;
such methods could both play a key role in preclinicalNMR Biomed. 2006; 19: 1035–1042
DOI: 10.1002/nbm
Table 1. Ex vivo determination of BCNU sensitivitya
Control 1 (dose 1) 2 (dose 1)
IC50SEM (mM) 42 5 54 4 62 1
p (versus control) — >0.05 <0.01
aCell lines from tumors excised from control, 1 treated and 2 treated
animals were assayed using an SRB growth inhibition assay to deter-
mine sensitivity to BCNU. The calculated mean IC50 SE for control
(n¼ 6), 1 (n¼ 3) and 2 (n¼ 3) are shown, and also p-values
determined using a standard Student’s t-test.
PROTON DIFFUSION AND SODIUM MRI 1041studies and provide huge advantages in the clinical
setting. Furthermore, imaging approaches offer great
potential for individualizing treatment response monitor-
ing, thus transitioning towards the tailoring of patient
treatments. In response to this goal, diffusion MRI has
been proven to be a useful and sensitive tool for
assessment of tumor response to therapy in preclinical
models (2,8–10,35). More importantly, diffusionMRI has
already taken the leap into clinical applications and has
shown great promise for predicting therapeutic outcome
well in advance of current methods (6,7). More recently,
sodium MRI has also been demonstrated to provide early
detection of response to therapy in various animal
models by detecting changes in TNa during cell death and
it has been shown to be highly correlative with diffusion
MRI (12,13).
In this study, we aimed to expand further our
investigation of diffusion and sodium imaging as viable
biomarkers of cancer therapy. The marginal difference
between tumor sensitivity and systemic toxicity continues
to pose a dilemma for therapeutic strategies. The problem
is exacerbated when alterations within the tumor may
occur during fractionated dosage schedules, leading to a
decrease in therapeutic effectiveness of the current
regimen. Hence it is imperative to be able to monitor
rapidly changes in therapeutic efficacy and to detect these
changes over time and in individual subjects. To
determine whether diffusion and sodium MRI could
provide a sensitive readout to detect changes in tumor
response to therapy, we employed the 9L gliosarcoma
model and various BCNU treatment regimens. Using a
BCNU dose of 1, our results demonstrated that sodium
MRI was able to detect rapidly tumor response to BCNU
therapy [Fig. 3(A)], which correlated highly with
concurrent diffusion data [Fig. 2(A)]. When a larger
chemotherapeutic dose (2) was used, a much greater
tumor response was detected after the initial adminis-
tration of the drug and a strong correlation was again
shown to exist between sodium and diffusion imaging.
These findings were also validated by observing tumor
growth kinetics, which confirmed that treatment with a
low dose of BCNU did indeed provide improved tumor
control and a higher dose of BCNU provided even greater
therapeutic benefit. Interestingly, our data suggested that
treatment with BCNU led to changes in tumor sensitivityCopyright # 2006 John Wiley & Sons, Ltd.to BCNU, which was especially apparent when a 2 dose
of BCNU was given to the animals. In comparison, a low
dose of BCNU (1) produced a similar response, as
detected by diffusion and sodium MRI, after both the
initial and subsequent dose of BCNU.
Furthermore, representative tumors were excised at the
end of MRI experiments from both 1 and 2 treated
groups to generate cell lines for testing BCNU sensitivity.
As previously described, the 1 doses of BCNU
produced similar responses whether after the initial dose
or the second dose (Figs 2 and 3). Using the SRB growth
inhibition assay, tumors taken after the second dose were
shown to have somewhat increased BCNU resistance,
which correlated with similar responsiveness as detected
by sodium and diffusion MRI. Interestingly, a 2 dose of
BCNU produced a much higher response after the initial
dose, but a subsequent equivalent dose produced a
greatly diminished response as quantified by sodium
and diffusion MRI. Chemo-sensitivity testing revealed
that tumors which received two high doses of therapy
had a much greater resistance to BCNU, which was
suggested earlier by both sodium and diffusion MRI
experiments. This observation is consistent with histori-
cal findings that treatment of 9L tumors with BCNU does
indeed lead to the emergence of drug resistance (28,36).
These data taken together, including ex vivo BCNU
sensitivity assays on excised tumors, validated the
hypothesis that shifts in BCNU sensitivity occur during
treatment, and that they are detectable using sodium and
diffusion MRI.CONCLUSION
The results of this study demonstrate the coherent ability
of diffusion and sodium MRI to reveal the efficacy of
tumor therapy in a few days following treatment in a dose-
dependent manner. The emerging tumor resistance to
BCNU was detected by both imaging modalities and was
confirmed by ex vivo assay of tumor cells derived from in
vivo treated tumors. Correlation between diffusion and
sodium continues to be present during alterations in tumor
sensitivity to treatment. These results support current
clinical trials of ADC as an indicator of tumor cellularity
during cancer therapy and demonstrate the complemen-
tary insights of 23Na MRI for tumor assessments to
treatment intervention. Finally, application of sodium
MRI may prove invaluable, especially in situations where
tissue motion can not be easily minimized.Acknowledgements
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